Notal Vision Appoints Dr. Susan Orr as Chief Medical Officer and Vice President of Medical Affairs
Accomplished Industry Executive Will Guide Strategy and Future Innovation
CHANTILLY, Va., Aug. 1, 2016 /PRNewswire/ -- Notal Vision, Ltd., a privately-held ophthalmic company that introduced ForeseeHome®, the first home-based monitoring system for patients with age-related macular degeneration (AMD), is pleased to announce the appointment of Susan Orr, OD, to Chief Medical Officer and Vice President of Medical Affairs. Dr. Orr brings more than 19 years of ophthalmic and retina strategy, development, and operational experience to Notal Vision.
"We are delighted to welcome Susan to the Notal Vision executive team," commented Quinton Oswald, Chief Executive Officer of Notal Vision. "Her broad ranging expertise will undoubtedly play an instrumental role in enhancing and driving the strategy for ForeseeHome®, as well as future clinical development programs. I am confident Susan's contributions will build on our momentum as we enter a pivotal phase in Notal Vision's growth."
Prior to joining Notal Vision, Dr. Orr served as Leader of Global Medical Affairs, Strategy, and Search & Evaluation for the Ophthalmology franchise at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson. During her tenure, Dr. Orr was involved in the creation of a retina medical affairs capability and led evaluation of clinical programs, as well as future pipeline development and strategic alignment. Prior to Janssen, Dr. Orr held several key leadership positions in business development, marketing, and research & development during her 17-year tenure at Alcon, a Novartis company. Susan received her Doctorate of Optometry from the University of Waterloo in Ontario, Canada and was in private practice for 10 years.
"Notal Vision is a true pioneer in AMD early detection and I'm honored to be joining this cutting-edge organization," said Dr. Orr. "I have tremendous respect for Quinton Oswald and his leadership team, and look forward to collaborating with such a talented group of people and the ophthalmic community to advance this technology. Regular telemonitoring to detect disease progression at its earliest stage is integral to the increasing need for patient-centric, outcomes-based medicine. ForeseeHome® is the only home-based Medicare-covered technology that has demonstrated the ability to detect choroidal neovascularization (CNV) earlier than standard care methods in a large NEI-sponsored trial, allowing for timely treatment and subsequent preservation of vision. Recent analyses of long-term AMD trials indicate that early detection of disease progression results in superior visual outcomes, reinforcing the importance of frequent observation to identify CNV. This technology offers patients and physicians the unprecedented ability to monitor disease progression in a way that is truly revolutionary."
About Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is the leading cause of severe vision loss and blindness in adults over age 50. The early stage of the disease, known as dry AMD, causes damage to the part of the retina called the macula, which is responsible for detailed central vision tasks like reading, driving and facial recognition. Patients with dry AMD may progress to the wet form of AMD, in which blood vessels form and may leak fluid and blood onto the retina. Several studies indicate that early detection of warning signs of disease progression provides patients the best chance to start therapy and maintain good vision and a better quality of life.
About ForeseeHome® AMD Monitoring Program
ForeseeHome Monitoring uses a technology known as preferential hyperacuity perimetry (PHP) to detect pattern defects across 500 points in the central 14° of a patient's retina. Over 1 million tests have been performed using the ForeseeHome® device. The test, which takes about 3 minutes per eye is simple to perform, and results are automatically transferred to the Notal Vision monitoring center and are available to the patient's eye doctor through a secure website. When a statistically significant change is detected on a patient's test, Notal Vision sends a prompt to the doctor to schedule a follow up appointment. To learn more, visit http://www.foreseehome.com
About Notal Vision™
Notal Vision was founded by two ophthalmologists, and is committed to providing retina specialists with innovative, home-based, technology solutions that support visual health in patients with AMD. The company's ForeseeHome® device is the first FDA-cleared home telemonitoring device that detects and characterizes visual distortion in AMD patients as an aid to monitoring progression to choroidal neovascularization. To learn more, visit http://www.foreseehome.com/about-notal.html
SOURCE Notal Vision, Inc.
Share this article